Geode Capital Management’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-722,355
| Closed | -$6.53M | – | 4605 |
|
|
2025
Q4 | $6.53M | Sell |
722,355
-6,365
| -0.9% | -$47.6K | ﹤0.01% | 2623 |
|
|
2025
Q3 | $2.27M | Buy |
728,720
+16,876
| +2% | +$44.7K | ﹤0.01% | 3135 |
|
|
2025
Q2 | $1.52M | Sell |
711,844
-751,259
| -51% | -$1.21M | ﹤0.01% | 3210 |
|
|
2025
Q1 | $1.68M | Buy |
1,463,103
+50,064
| +4% | +$86K | ﹤0.01% | 3111 |
|
|
2024
Q4 | $3.1M | Buy |
1,413,039
+21,337
| +2% | +$48.4K | ﹤0.01% | 2972 |
|
|
2024
Q3 | $3.03M | Buy |
1,391,702
+77,350
| +6% | +$178K | ﹤0.01% | 2984 |
|
|
2024
Q2 | $3.04M | Buy |
1,314,352
+207,542
| +19% | +$862K | ﹤0.01% | 2978 |
|
|
2024
Q1 | $6.09M | Buy |
1,106,810
+81,191
| +8% | +$371K | ﹤0.01% | 2589 |
|
|
2023
Q4 | $2.53M | Buy |
1,025,619
+49,809
| +5% | +$473K | ﹤0.01% | 3019 |
|
|
2023
Q3 | $33.9M | Buy |
975,810
+200,090
| +26% | +$6.92M | ﹤0.01% | 1496 |
|
|
2023
Q2 | $25.4M | Buy |
775,720
+238,578
| +44% | +$8.22M | ﹤0.01% | 1694 |
|
|
2023
Q1 | $18M | Buy |
537,142
+27,728
| +5% | +$1.08M | ﹤0.01% | 1874 |
|
|
2022
Q4 | $16.7M | Buy |
509,414
+100,452
| +25% | +$2.98M | ﹤0.01% | 1896 |
|
|
2022
Q3 | $14.3M | Buy |
408,962
+122,759
| +43% | +$2.72M | ﹤0.01% | 1988 |
|
|
2022
Q2 | $3.5M | Buy |
286,203
+90,551
| +46% | +$1.35M | ﹤0.01% | 2889 |
|
|
2022
Q1 | $2.65M | Buy |
195,652
+8,113
| +4% | +$108K | ﹤0.01% | 3109 |
|
|
2021
Q4 | $3.72M | Buy |
+187,539
| New | +$3.55M | ﹤0.01% | 3053 |
|
Other funds holding VTYX
Geode Capital Management's VTYX Position: Q1 2026 in Review
Geode Capital Management sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 722,355 shares — an estimated $6.53M sold.
Geode Capital Management first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $33.9M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Geode Capital Management reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Geode Capital Management sold 722,355 Ventyx Biosciences shares in Q1 2026, an estimated $6.53M.
- Geode Capital Management first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Geode Capital Management's Ventyx Biosciences position peaked at $33.9M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.